1) Haematologica 2010; 95[suppl.2]:, abs. 0687
SINGLE-AGENT LENALIDOMIDE FOR THE TREATMENT OF RELAPSED OR REFRACTORY AGGRESSIVE LYMPHOMA PATIENTS |
2) Haematologica 2010; 95[suppl.2]:, abs. 1685
CXCR7 REGULATE CXCR4/SDF-1 MEDIATED HEMATOPOIETIC SUPPORTING ACTIVITY OF STROMAL CELLS BY CONTROLING EXTRACELLULAR SDF-1 CONCENTRATIONS |
3) Haematologica 2010; 95[suppl.2]:1, abs. 0001
HIGH-RESOLUTION PHARMACOGENETIC PROFILES OF GENES INVOLVED IN DRUG ABSORPTION, DISTRIBUTION, METABOLISM AND ELIMINATION IN ADULT PHILADELPHIA-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS |
4) Haematologica 2010; 95[suppl.2]:1, abs. 0002
INTACT APOPTOSIS SIGNALING IN PEDIATRIC ALL IS ASSOCIATED WITH PROLONGED NOD/SCID ENGRAFTMENT, LOW EXPRESSION OF ANTI-APOPTOTIC MOLECULES AND FAVORABLE PATIENT OUTCOME |
5) Haematologica 2010; 95[suppl.2]:10, abs. 0023
QUANTITATIVE ASSESSMENT OF WT1 EXPRESSION FOR MONITORING MINIMAL RESIDUAL DISEASE IN ACUTE LEUKEMIA PATIENTS |
6) Haematologica 2010; 95[suppl.2]:10, abs. 0024
IDENTIFICATION OF CRITICAL TUMOR SUPPRESSOR GENES (TSGS) AND NEW PROGNOSTIC FACTORS IN HUMAN MYELOID DISORDERS USING RETROVIRAL INSERTION MUTAGENESIS |
7) Haematologica 2010; 95[suppl.2]:10, abs. 0025
CHARACTERISATION OF AML1-ETO9A LEUKAEMIOGENESIS USING AN INDUCIBLE MURINE MODEL |
8) Haematologica 2010; 95[suppl.2]:100, abs. 0255
OPTIMIZED RADIOLOGICAL DIAGNOSIS OF HEPATIC CANDIDIASIS DURING THE TREATMENT OF ACUTE LEUKEMIAS |
9) Haematologica 2010; 95[suppl.2]:100, abs. 0256
INFECTIONS DUE TO KLEBSIELLA IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES: RISK FACTORS FOR SEVERE SEPSIS/SEPTIC SHOCK AND MORTALITY |
10) Haematologica 2010; 95[suppl.2]:101, abs. 0257
THE USE OF CARDIAC BIOMARKERS IN DETECTION OF CARDIOTOXICITY ASSOCIATED WITH CONVENTIONAL AND HIGH-DOSE CHEMOTHERAPY FOR ACUTE LEUKEMIA |
11) Haematologica 2010; 95[suppl.2]:101, abs. 0258
IMPLEMENTATION OF A CLINICAL PRACTICE GUIDELINE FOR CHILDREN WITH CANCER PRESENTING WITH FEVER AT EMERGENCY ROOM |
12) Haematologica 2010; 95[suppl.2]:101, abs. 0259
EARLY DIAGNOSIS, GUIDANCE OF THERAPY AND IDENTIFYING HIGH MORTALITY SUBGROUPS OF NEUTROPENIC PATIENTS WITH SEPSIS: ROLE OF PROCALCITONIN |
13) Haematologica 2010; 95[suppl.2]:102, abs. 0260
HEPATITIS B INFECTION IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES, CLINICO-BIOLOGICAL EXPRESSION AND OUTCOME |
14) Haematologica 2010; 95[suppl.2]:102, abs. 0261
IMMUNOGLOBULIN LEVELS AND INFECTIONS IN PATIENTS RECEIVING RITUXIMAB EITHER AS INDUCTION OR AS MAINTENANCE THERAPY |
15) Haematologica 2010; 95[suppl.2]:102, abs. 0262
CYTOMEGALOVIRUS REACTIVATION AFTER AUTOLOGOUS STEM CELL TRANSPLANT FOR B-CELL MALIGNANCIES: SOMETHING TO DEAL WITH. A PROSPECTIVE STUDY ON 92 CONSECUTIVE PATIENTS |
16) Haematologica 2010; 95[suppl.2]:103, abs. 0263
VORICONAZOLE OR ITRACONAZOLE FOR PREVENTION OF INVASIVE FUNGAL INFECTIONS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLOHCT) - FOCUS ON PATIENT PREFERENCE AND LONG-TERM TOLERABILITY |
17) Haematologica 2010; 95[suppl.2]:103, abs. 0264
CYTOMEGALOVIRUS MAY HAVE A ROLE IN THE PATHOPHYSIOLOGY OF CHRONIC IDIOPATHIC NEUTROPENIA |
18) Haematologica 2010; 95[suppl.2]:104, abs. 0265
LATE ONSET NEUTROPENIA IN VLBW NEONATES |
19) Haematologica 2010; 95[suppl.2]:104, abs. 0266
IMMUNE DYSFUNCTION IN PATIENTS WITH GAUCHER DISEASE: IMPACT OF DISEASE SEVERITY AND ENZYME REPLACEMENT THERAPY |
20) Haematologica 2010; 95[suppl.2]:104, abs. 0267
COMPARABILITY OF A NEW BIOSIMILAR GRANULOCYTE-COLONY STIMULATING FACTOR WITH ITS REFERENCE PRODUCT |
21) Haematologica 2010; 95[suppl.2]:105, abs. 0268
CLINICAL AND BIOLOGICAL SPECTRUM OF LARGE GRANULAR LYMPHOCYTE PROLIFERATIONS |
22) Haematologica 2010; 95[suppl.2]:105, abs. 0269
NEUTROPHIL APOPTOSIS IN NEUTROPENIC PATIENTS WITH HEPATITIS C INFECTION: ROLE OF CASPASES 3, 10, AND GM-CSF |
23) Haematologica 2010; 95[suppl.2]:106, abs. 0270
FRONTLINE TREATMENT WITH THE COMBINATION FLUDARABINE-CYCLOPHOSPHAMIDE IN LOW-GRADE NON-FOLLICULAR NON-HODGKIN LYMPHOMA: A LONG TERM UPDATING OF GISL LL02 TRIAL |
24) Haematologica 2010; 95[suppl.2]:106, abs. 0271
EFFICACY AND SAFETY OF BORTEZOMIB AND RITUXIMAB ASSOCIATION IN RELAPSED/REFRACTORY INDOLENT NON-FOLLICULAR AND MANTLE CELL LYMPHOMA: FINAL RESULTS OF PHASE II STUDY BY INTERGRUPPO ITALIANO LINFOMI |
25) Haematologica 2010; 95[suppl.2]:107, abs. 0272
TWO YEAR FOLLOW UP OF THE CANADIAN TOSITUMOMAB AND I131 TOSITUMOMAB (TST/I131-TST) EXPERIENCE: THE LARGEST PHASE II STUDY WITH RIT IN INDOLENT NON HODGKIN LYMPHOMA WITH PRIOR RITUXIMAB (R) TREATMENT |